CYP3A4 Antibodies

Santa Cruz Biotechnology provides a broad selection of CYP3A4 monoclonal antibodies for research focused on understanding this critical enzyme. CYP3A4 Antibodies are validated for western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), flow cytometry (FCM), and enzyme-linked immunosorbent assay (ELISA). CYP3A4 is a key enzyme in the cytochrome P450 family, responsible for the metabolism of a significant proportion of drugs and xenobiotics in the liver. Its activity is crucial for drug clearance and can influence individual responses to medications, making it an important target for pharmacogenomic studies. Understanding CYP3A4 function and regulation is essential for optimizing therapeutic strategies and minimizing adverse drug reactions. CYP3A4 plays a vital role in maintaining cellular homeostasis and drug metabolism efficiency. Researchers frequently study CYP3A4 to better understand drug interactions and metabolic pathways. Current investigations focus on how CYP3A4 expression levels affect patient responses to various medications. Santa Cruz Biotechnology monoclonal antibodies enable researchers worldwide to advance our understanding of drug metabolism and its impact on personalized medicine.